Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 6, pp 1443–1453 | Cite as

The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis

  • Camila Hartmann
  • Natasha Ludmila Bosch
  • Luara de Aragão Miguita
  • Elise Tierie
  • Lídia Zytinski
  • Cristina Pellegrino Baena
Review Article
  • 189 Downloads

Abstract

Background Ivabradine is currently indicated to lower heart rate in Heart Failure with Reduced Ejection Fraction (HFrEF) patients. However its effect apart from beta-blockers is not clear. Aim of the review To study the additional effect of ivabradine, apart from the effect of beta-blockers, on cardiovascular death, all-cause mortality, hospitalization due to HF and heart rate in HFrEF population. Method Electronic searches were conducted up to June 2016 to include randomized controlled trials where ivabradine was compared to a control group. Relative risks RRs and their 95% confidence intervals (CI 95%) were pooled and the random and fixed effect were used to summarize the results according to heterogeneity levels. Heterogeneity among studies was measured by the I-squared statistic Results Of 1790 studies, seven met the inclusion criteria for the systematic review and meta-analysis. The population consisted of 17,747 patients. Risk of bias was generally high for beta-blocker doses lower than recommended. Interventions lasted 1.5–22.9 months and pooled relative risks RR (95%) for all-cause mortality, cardiovascular death and hospitalization for HF were 0.98 (0.90–1.06); 0.99 (0.91–1.08); and 0.87 (0.68–1.12) respectively. Heart rate (CI 95%) decreased by 8.7 (6.37–11.03) beats per minute with ivabradine compared to the control group. Subgroup analysis by beta-blocker dose showed that for patients on recommended treatment (at least 50% of the beta-blocker target dose), heart rate (CI 95%) decreased by 4.70 (3.67–5.73), whereas for patients not on recommended treatment or with unreported dose, heart rate decreased by 8.60 (8.13–9.08). Conclusion Ivabradine significantly reduced heart rate and its additional effect on heart rate appears to be inversely correlated with the dose of beta-blocker. It showed no significant effect for all-cause mortality, cardiovascular death and hospitalization due to HF. Unreported beta-blocker doses and beta-blocker doses lower than recommended limited the conclusions.

Keywords

Beta-blockers Heart failure Heart rate Ivabradine Left ventricular dysfunction Systematic review 

Notes

Acknowledgements

We would like to thank the graduate program in health sciences of Pontifícia Universidade Católica do Paraná (PUCPR).

Funding

Source data for this systematic review were collected and analyzed by the independent authors. All cost of the research was funded by the authors.

Conflicts of interest

Camila Hartmann has received speaker’s fees from Cristália. Lídia Zytynski Moura has received speaker honoraria and research support from Servier and EMS. Natasha Ludmila Bosch, Luara de Aragão Miguita, Elise Tierie, and Cristina Pellegrino Baena declare no potential conflicts of interest that might be relevant to this manuscript.

Supplementary material

11096_2018_715_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 11 kb)

References

  1. 1.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–200.CrossRefGoogle Scholar
  2. 2.
    Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel L, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMedGoogle Scholar
  5. 5.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.CrossRefGoogle Scholar
  7. 7.
    Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60(15):1323–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.CrossRefGoogle Scholar
  10. 10.
    Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. www.handbook.cochrane.org.
  11. 11.
    Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Mansour S, Youssef A, Rayan M, Saleh MA. Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure. Egypt Heart J. 2011;63:79–85.CrossRefGoogle Scholar
  13. 13.
    Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, et al. Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15(4):349–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P, et al. Effect or Carvedilol, ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsutsui H, Momomura S, Yamashina A, Ogawa H, Shimokawa H, Kihara Y, et al. Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure—a randomized, double-blind, placebo-controlled phase II study. Circ J. 2016;80(3):668–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Swedberg K, Komajda M, Böhm M, Robertson M, Tavazzi L, Ford I, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? JACC. 2012;59(22):1938–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Lechat P, Brunhuber KW, Hoffmann R, Kühn P, Nesser HJ, Slany J, et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.CrossRefGoogle Scholar
  18. 18.
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.CrossRefGoogle Scholar
  19. 19.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.CrossRefPubMedGoogle Scholar
  20. 20.
    McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886–94.CrossRefPubMedGoogle Scholar
  22. 22.
    Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 1994;15(2):164–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Kitai T, Tang WH. Pathophysiologic insights into heart rate reduction in heart failure: implications in the use of beta-blockers and ivabradine. Curr Treat Options Cardiovasc Med. 2016;18(2):13.CrossRefPubMedGoogle Scholar
  24. 24.
    Hidalgo FJ, Anguita M, Castillo JC, Rodríguez S, Pardo L, Durán E, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol. 2016;217:7–11.CrossRefPubMedGoogle Scholar
  25. 25.
    Grande D, Iacoviello M, Aspromonte N. The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Fail Rev. 2018;23(4):527–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777–84.CrossRefPubMedGoogle Scholar
  27. 27.
    Reunanen A, Karjalainen J, Ristola P, Heliövaara M, Knekt P, Aromaa A. Heart rate and mortality. J Intern Med. 2000;247(2):231–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016;70:129–35.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Camila Hartmann
    • 1
  • Natasha Ludmila Bosch
    • 1
  • Luara de Aragão Miguita
    • 1
  • Elise Tierie
    • 1
    • 2
  • Lídia Zytinski
    • 1
  • Cristina Pellegrino Baena
    • 1
  1. 1.Pontificia Universidade Católica do ParanáCuritibaBrazil
  2. 2.Erasmus MCRotterdamThe Netherlands

Personalised recommendations